Journal
DIABETES OBESITY & METABOLISM
Volume 15, Issue 3, Pages 204-212Publisher
WILEY
DOI: 10.1111/dom.12012
Keywords
GLP-1 analogue; type 2 diabetes
Categories
Funding
- National Institute of Health Research (NIHR), UK
- Berlin-Chemie AG/Menarini
- Eli Lilly Co
- Merck Sharp Dohme
- Novartis Pharma
- AstraZeneca
- Boehringer-Ingelheim
- GlaxoSmithKline
- Lilly Deutschland GmbH
- MetaCure Inc.
- Roche Pharma AG
- Novo Nordisk Pharma GmbH
- Tolerx Inc.
- Berlin Chemie AG/Menarini
- Hoffman-La Roche
- Janssen Global Services
- Novo Nordisk A/S
- Sanofi
- Takeda
- Versartis
- Novo Nordisk
- Becton Dickinson
- Merck Co.
- Bristol-Myers Squibb
- Novartis
- Johnson and Johnson
- Servier
- National Institute for Health Research [NF-SI-0508-10272] Funding Source: researchfish
Ask authors/readers for more resources
Aims To investigate efficacy and safety of dual therapy with liraglutide and metformin in comparison to glimepiride and metformin, and metformin monotherapy over 2?years in patients with type 2 diabetes. Methods In the 26-week the Liraglutide Effect and Action in Diabetes (LEAD)-2 core trial, patients (n?=?1091) were randomized (2?:?2?:?2?:?1:?2) to liraglutide (0.6, 1.2 or 1.8?mg once-daily), placebo or glimepiride; all with metformin. Patients were enrolled if they were 1880?years old with HbA1c 7.011.0% (previous monotherapy =3?months), or 7.010.0% (previous combination therapy =3?months), and body mass index =40?kg/m2. Patients completing the 26-week double-blinded phase could enter an 18-month open-label extension. Results HbA1c decreased significantly with liraglutide (0.4% with 0.6?mg, 0.6% with 1.2 and 1.8?mg) versus 0.3% increase with metformin monotherapy (p?
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available